share_log

Aurora Vs. Canopy & Tilray: Which NASDAQ-Listed Cannabis Stock Offers The Best Growth Potential?

Aurora Vs. Canopy & Tilray: Which NASDAQ-Listed Cannabis Stock Offers The Best Growth Potential?

Aurora Vs. Canopy & Tilray:哪家納斯達克上市的大麻股票提供最佳增長潛力?
Benzinga ·  11/07 23:15

Aurora Cannabis Inc. (NASDAQ:ACB) recently reported strong quarterly earnings that outpaced market expectations, despite a downturn across the cannabis sector.

大麻股公司Aurora Cannabis Inc.(納斯達克股票代碼:ACB)最近報告顯示季度收入強勁,超出市場預期,儘管大麻行業板塊整體走低。

Aurora's share price fell 18% following the earnings report, reflecting broader sector pressures, with the MSOS ETF down 29%. As of this morning, November 7, 2024, Aurora's stock is trading at $5.25 in pre-market, showing a 2.54% increase from its previous close.

Aurora的股價在業績發佈後下跌了18%,反映了更廣泛的行業壓力,而MSOS ETF下跌了29%。截至2024年11月7日,今早Aurora的股票在盤前交易中報價爲5.25美元,比前一交易日收盤價上漲了2.54%。

"Despite having no U.S. exposure, Aurora surpassed consensus estimates on sales and EBITDA, encouraging guidance for the December quarter," observed analyst Pablo Zuanic of Zuanic & Associates.

「儘管沒有美國業務,Aurora在銷售和EBITDA方面超過共識預期,爲12月季度提供了鼓舞人心的指引,」Zuanic&Associates的分析師Pablo Zuanic指出。

  • Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter here. You can't afford to miss out if you're serious about the business.
  • 在Benzinga獲取獨家分析,並每天免費獲得關於大麻業務和市場的頭條新聞。立即訂閱我們的通訊,認真對待業務,您不容錯過。

International Medical Cannabis Growth Drives Revenue

國際醫療大麻增長推動營業收入

Aurora's international medical cannabis (MMJ) business significantly bolstered its revenue, with European sales doubling quarter-over-quarter to $20 million, led by strong demand in Germany and Poland.

Aurora的國際醫療大麻(MMJ)業務大幅增加了其營業收入,歐洲銷售額同比增加到2000萬美元,主要受到德國和波蘭需求旺盛的推動。

Australian MMJ sales also rose from $9.3 million to $15.1 million, benefiting from an August inventory drawdown following the MedReleaf Australia acquisition.

澳大利亞的醫療大麻銷售額也從930萬美元增至1510萬美元,在收購MedReleaf澳大利亞後,得益於8月出庫存的影響。

Profit Margins Reflect International Expansion

利潤率反映國際擴張

The company's profitability has improved as higher-margin international markets now make up 57% of Aurora's global MMJ sales from 42% a year ago. This boosted adjusted cash gross margins to 68% for MMJ products, a 5% increase year-over-year, with total company margins rising 450 basis points to over 55%.

公司的盈利能力得到改善,因爲高利潤的國際市場現在佔到了Aurora全球醫療大麻銷售的57%,而一年前只有42%。這使得醫療大麻產品的調整現金毛利潤率提高至68%,同比增長5%,整個公司的毛利率上升了450個點子,超過55%。

Operating expenses remained steady at $35 million per quarter, resulting in an EBITDA margin increase from 5% to 12% year-over-year.

營業費用保持穩定,每季度爲3500萬美元,導致EBITDA毛利率同比從5%增加至12%。

Read Also: Cannabis Stocks Collapse After Trump Win: Major Players See Double-Digit Declines At Wednesday's Close

閱讀更多:特朗普當選後大麻股暴跌:主要股票雙位數下跌

December Quarter Guidance And Challenges

十二月季度指導與挑戰

Aurora anticipates stable sales and EBITDA for the December quarter, exceeding consensus by 9% and 90%, respectively. The outlook includes a seasonal decline in its propagation business but projects positive EBITDA and free cash flow, supported by Aurora's net cash position of $27 million (cash of $85 million against $58 million in Bevo-related debt).

Aurora預計12月季度銷售額和EBITDA保持穩定,分別超過共識9%和90%。展望包括其繁殖業務的季節性下降,但預計EBITDA和自由現金流爲正,得到Aurora淨現金頭寸爲2700萬美元(現金8500萬美元,貝沃相關債務5800萬美元)的支持。

Zuanic noted that international growth remains promising, although "shipments can be inconsistent, making end-market growth predictions difficult."

Zuanic指出,國際增長仍然具有前景,儘管"出貨可能不穩定,使得最終市場增長預測困難"。

Valuation Compared To Peers

與同行相比的估值

According to Zuanic, with a valuation of 1.4x its annualized sales, Aurora appears undervalued compared to competitors Tilray (NASDAQ:TLRY) and Canopy Growth (NASDAQ:CGC), which trade at multiples of 3-4x sales.

根據Zuanic的說法,以其年銷售額的1.4倍估值計算,Aurora看起來被低估,與競爭對手Tilray(納斯達克:TLRY)和大麻股(納斯達克:CGC)相比,後者的銷售倍數爲3-4倍。

"Though business models differ, operational trends and lower valuation offer potential upside for ACB shares," Zuanic commented. Aurora's combination of higher-margin international revenue and more conservative valuation may present an opportunity amid sector volatility.

「儘管業務模式不同,運營趨勢和較低估值爲ACb股票提供了潛在上漲空間,」Zuanic評論道。在行業板塊波動中,極光的高毛利國際營收與更保守的估值結合,可能帶來機會。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論